Similar articles

• Intraperitoneal therapy for ovarian cancer: why has it not become standard?

  Rowan K. Rowan K. J Natl Cancer Inst. 2009 Jun 3;101(11):775-7. doi: 10.1093/jnci/djp151. Epub 2009 May 26. J Natl Cancer Inst. 2009. PMID: 19470952 No abstract available.
• Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.

  Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK, Frick KD. Bristow RE, et al. Gynecol Oncol. 2007 Sep;106(3):476-81. doi: 10.1016/j.ygyno.2007.05.043. Epub 2007 Aug 3. Gynecol Oncol. 2007. PMID: 17688927
• Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.

  Markman M, Walker JL. Markman M, et al. J Clin Oncol. 2006 Feb 20;24(6):988-94. doi: 10.1200/JCO.2005.05.2456. Epub 2006 Feb 6. J Clin Oncol. 2006. PMID: 16461779 Review. No abstract available.
• Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?

  Petignat P, du Bois A, Bruchim I, Fink D, Provencher DM. Petignat P, et al. Crit Rev Oncol Hematol. 2007 May;62(2):137-47. doi: 10.1016/j.critrevonc.2006.11.009. Epub 2006 Dec 26. Crit Rev Oncol Hematol. 2007. PMID: 17188887 Review.
• Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.

  Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Greimel ER, et al. J Clin Oncol. 2006 Feb 1;24(4):579-86. doi: 10.1200/JCO.2005.02.4067. J Clin Oncol. 2006. PMID: 16446330 Clinical Trial.